Study of the Efficacy and Safety of Etanercept Treatment in Patients With SAPHO Syndrome
Status:
Recruiting
Trial end date:
2028-10-18
Target enrollment:
Participant gender:
Summary
The study includes adult patients with SAPHO syndrome (ORPHA: 793), meeting the modified
classification criteria according to Kahn (2003), with the ineffectiveness of standard
treatment (patient's global assessment of the disease on the VAS scale greater than or equal
to 4 cm with accompanying pain on the VAS scale greater than or equal to 4 cm) treated with
non-steroidal anti-inflammatory drugs in a stable dose for at least 4 weeks and/or classical
disease-modifying antirheumatic drugs in stable doses for at least 12 weeks.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland